Centaurus Financial Inc. Acquires 357 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Centaurus Financial Inc. lifted its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 13.0% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,103 shares of the medical equipment provider’s stock after buying an additional 357 shares during the period. Centaurus Financial Inc.’s holdings in Lantheus were worth $341,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in LNTH. Moloney Securities Asset Management LLC purchased a new stake in Lantheus during the third quarter valued at approximately $1,066,000. Hancock Whitney Corp raised its holdings in Lantheus by 265.6% during the 1st quarter. Hancock Whitney Corp now owns 20,151 shares of the medical equipment provider’s stock valued at $1,254,000 after buying an additional 14,639 shares during the period. Wealth Enhancement Advisory Services LLC bought a new stake in Lantheus in the second quarter worth $290,000. Van ECK Associates Corp boosted its stake in Lantheus by 58.6% during the third quarter. Van ECK Associates Corp now owns 58,472 shares of the medical equipment provider’s stock worth $6,469,000 after buying an additional 21,604 shares during the period. Finally, Swedbank AB increased its position in Lantheus by 21.1% during the third quarter. Swedbank AB now owns 722,243 shares of the medical equipment provider’s stock valued at $79,266,000 after acquiring an additional 125,843 shares during the last quarter. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Lantheus Stock Down 1.6 %

LNTH opened at $89.53 on Wednesday. The stock’s fifty day moving average is $102.80 and its two-hundred day moving average is $97.04. The company has a market capitalization of $6.22 billion, a P/E ratio of 14.90 and a beta of 0.51. Lantheus Holdings, Inc. has a 52 week low of $50.20 and a 52 week high of $126.89.

Analysts Set New Price Targets

A number of equities analysts recently commented on LNTH shares. Redburn Atlantic started coverage on shares of Lantheus in a report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price target on the stock. Truist Financial reaffirmed a “buy” rating and set a $120.00 target price (down previously from $135.00) on shares of Lantheus in a research note on Friday, November 8th. StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Finally, JMP Securities cut their price objective on Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a research report on Thursday, November 7th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $122.50.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.